ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum

Gynecologic Oncology

Volumn 77, Issue 1, 2000, Pages 105-111

  Garrett, Audrey P ^a   Ng, Shu Wing ^a   Muto, Michael G ^a   Welch, William R ^b   Bell, Debra A ^c   Berkowitz, Ross S ^a   Mok, Samuel C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

K ras; Multifocality; Oncogene; Ovarian carcinoma; Peritoneal carcinoma

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN;

ARTICLE; CARCINOGENESIS; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; GENE ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE K RAS; OVARY CARCINOMA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DOMAIN; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0034049495     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.5747     Document Type: Article

References (34)

1. Kowalski L D, Kanbour A I, Price F V, Finkelstein S D, Christopherson W A, Seski J C, Naus G J, Burnham J A, Kanbour-Shakir A, Edwards R P. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma. Cancer. 79:1997;1587-1594.
2. Killackey M A, Davis A R. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. Gynecol Oncol. 51:1993;171-174.
3. Bloss J D, Liao S, Buller R E, Manetta A, Berman M L, McMeekin S, Bloss L P, DiSaia P J. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol. 50:1993;347-351.
4. Schorge J O, Muto M G, Welch W R, Bandera C A, Rubin S C, Bell D A, Berkowitz R S, Mok S C. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst. 90:1998;841-845.
5. Kannerstein M, Churg J. Peritoneal mesothelioma. Hum Pathol. 8:1977;83-94.
6. Eltabbakh G H, Piver M S. Extraovarian primary peritoneal carcinoma. Oncology. 12:1998;813-826.
7. Muto M G, Welch W R, Mok S C, Bandera C A, Fishbaugh P M, Tsao S, Lau C C, Goodman H M, Knapp R C, Berkowitz R S. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res. 55:1995;490-492.
8. Bandera C A, Schorge J O, Muto M G, Berkowitz R S, Rubin S C, Mok S C. Germline BRCA1 mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol. 92:1998;596-600.
9. Bos J L. ras oncogenes in human cancer: a review. Cancer Res. 49:1989;4682-4689.
10. DeVivo I, Marion M J, Smith S J, Carney W P, Brandt-Rauf P W. Mutant C-Ki-ras p21 protein in chemical carcinogenesis in humans exposed to vinyl chloride. Cancer Causes Control. 5:1994;273-278.
11. Plattner R, Gupta S, Khosravi-Far R, Sato K Y, Perucho M, Der C J, Stanbridge E J. Differential contribution of the ERK and JNK mitogen activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells. Oncogene. 18:1999;1807-1817.
12. Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J. Kras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer. 79:1997;1581-1586.
13. Mok S C, Bell D A, Knapp R C, Fishbaugh P M, Welch W R, Muto M G, Berkowitz R S, Tsao S W. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 53:1993;1489-1492.
14. Cuatrecasas M, Erill N, Musulen E, Costa I, Matias-Guiu X, Prat J. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients. Cancer. 82:1998;1088-1095.
15. Teneriello M G, Ebina M, Linnoila R I, Henry M, Nash J D, Park R C, Birrer M J. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 53:1993;3103-3108.
16. Yaginuma Y, Yamashita K, Kuzumaki N, Fujita M, Shimizu T. ras oncogene product p21 expression and prognosis of human ovarian tumors. Gynecol Oncol. 46:1992;45-50.
17. Hesketh R. The Oncogene Facts Book. 1995;Academic Press, London. p. 225-234.
18. Scambia G, Catozzi L, Panici P B, Ferrandina G, Coronetta F, Barozzi R, Baiocchi G, Uccelli L, Piffanelli A, Mancuso S. Expression of ras oncogene p21 protein in normal and neoplastic ovarian tissues: correlation with histopathologic features and receptors for estrogen, progesterone, and epidermal growth factor. Am J Obstet Gynecol. 168:1993;71-78.
19. Patton S E, Martin M L, Nelsen L L, Fang X, Mills G B, Bast R C, Ostrowski M C. Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines. Cancer Res. 58:1998;2253-2259.
20. K gene in a human ovarian carcinoma. Science. 223:1984;698-701.
21. Boltz E M, Kefford R F, Leary J A, Houghton C R, Friedlander M L. Amplification of c-ras-Ki oncogene in human ovarian tumors. Int J Cancer. 43:1989;428-430.
22. Fukomoto M, Estenson R D, Sha L, Oakley G J, Twiggs L B, Adocock L L, Carson L F, Roninson I B. Association of ki-ras with amplified DNA sequences, detected in human ovarian carcinomas by a modified in-gel renaturation assay. Cancer Res. 49:1989;1693-1697.
23. Katsaros D, Theillet C, Zola P, Louason G, Sanfilippo B, Isaia E, Arisio R, Giardina G, Sismondi P. Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients. Anticancer Res. 15:1995;1501-1510.
24. Enomoto T, Weghorst C M, Tanizawa O, Rice J M. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol. 139:1991;777-785.
25. Taylor S J, Shalloway D. Cell cycle-dependent activation of Ras. Curr Biol. 6:1996;1621-1627.
26. Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary: case report. Am J Obstet Gynecol. 77:1959;197-200.
27. Fromm G L, Gershenson D M, Silva E G. Papillary serous carcinoma of the peritoneum. Obstet Gynecol. 75:1990;75-89.
28. Eltabbakh G H, Piver M S, Natarajan N, Mettlin C J. Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet Gynecol. 91:1998;254-259.
29. Karlan B Y, Baldwin R L, Lopez-Luevanos E, Raffel L J, Barbuto D, Narod S, Platt L D. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: Implications for ovarian cancer screening. Am J Obstet Gynecol. 180:1999;917-928.
30. Huang L W, Garrett A P, Schorge J O, Muto M G, Welch W R, Bell D A, Berkowitz R S, Mok S C. Detailed mapping of chromosome 6q in papillary serous carcinoma of the peritoneum compared with high-grade late-stage invasive serous epithelial ovarian carcinomas. Gynecol Oncol. 72:1999;524.
31. Shibata K, Kikkawa F, Nawa A, Thant A A, Naruse K, Mizutani S, Hamaguchi M. Both focal adhesion kinase and c-Ras are required for the enhanced matrix metalloproteinase 9 secretion by fibronectin in ovarian cancer cells. Cancer Res. 58:1998;900-903.
32. Rodenburg C J, Koelma I A, Nap M, Fleuren G J. Immunohistochemical detection of the ras oncogene product p21 in advanced ovarian cancer. Arch Pathol Lab Med. 112:1988;151-154.
33. Scambia G, Masciullo V, Panici P B, Marone M, Ferrandina G, Todaro N, Bellacosa A, Jain S K, Neri G, Piffanelli A, Mancuso S. Prognostic significance of ras/p21 alterations in human ovarian cancer. Br J Cancer. 75:1997;1547-1553.
34. Mandai M, Konishi I, Komatsu T, Mori T, Arao S, Nomura H, Kanda Y, Hiai H, Fukomoto M. Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and k-ras mutation in ovarian carcinoma: correlation with tumor progression and nm23 gene expression. Br J Cancer. 72:1995;691-695.